Resultados de búsqueda - Brian Wynne
- Mostrando 1 - 12 Resultados de 12
-
1
-
2
-
3
-
4
-
5
Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies por Mark Underwood, Rimgaile Urbaityte, Ruolan Wang, Joe Horton, James Oyee, Brian Wynne, Dainielle Fox, Bryn Jones, Choy Man, Jörg Sievers
Publicado 2024-03-01
Artículo -
6
Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials por Frank Spinelli, Manyu Prakash, Jill Slater, Mike van der Kolk, Niccolò Bassani, Richard Grove, Brian Wynne, Jean van Wyk, Andrew Clark
Publicado 2021-07-01
Artículo -
7
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEM... por Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk
Publicado 2021-12-01
Artículo -
8
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144 por Ruolan Wang, Jonathan Wright, Parminder Saggu, Mounir Ait-Khaled, Riya Moodley, Chris M. Parry, Thomas Lutz, Daniel Podzamczer, Richard Moore, Miguel Górgolas Hernández-Mora, Clifford Kinder, Brian Wynne, Jean van Wyk, Mark Underwood
Publicado 2023-06-01
Artículo -
9
TROCA PARA UM REGIME COM 2 MEDICAMENTOS DOLUTEGRAVIR / LAMIVUDINA (DTG / 3TC) EM DOSE FIXA COMBINADA É NÃO INFERIOR A CONTINUAR COM UM REGIME DE 3 MEDICAMENTOS POR 48 SEMANAS EM UM... por Josep M. Llibre, Carlos Brites, Chien-yu Cheng, Olayemi Osiyemi, Carlos Galera, Laurent Hocqueloux, Franco Maggiolo, Olaf Degen, Libby Blair, Brian Wynne, James Oyee, Mark Underwood, Lloyd Curtis, Gilda Bontempo, Jean van Wyk, Jucival Fernandes
Publicado 2022-01-01
Artículo -
10
Efficacy and safety of switching to dolutegravir/lamivudine in virologically suppressed people with HIV-1 aged ≥ 50 years: week 48 pooled results from the TANGO and SALSA studies... por Sharon Walmsley, Don E. Smith, Miguel Górgolas, Pedro E. Cahn, Thomas Lutz, Karine Lacombe, Princy N. Kumar, Brian Wynne, Richard Grove, Gilda Bontempo, Riya Moodley, Chinyere Okoli, Michelle Kisare, Bryn Jones, Andrew Clark, Mounir Ait-Khaled
Publicado 2024-03-01
Artículo -
11
TROCA PARA A COMBINAÇÃO DE DOSE FIXA DE DOLUTEGRAVIR/LAMIVUDINA É NÃO INFERIOR A UM REGIME BASEADO EM TENOFOVIR ALAFENAMIDA NA MANUTENÇÃO DA SUPRESSÃO VIROLÓGICA POR 144 SEMANAS (E... por Olayemi Osiyemi, Faïza Ajana, Fiona Bisshop, Stéphane de Wit, Joaquín Portilla, Jean-pierre Routy, Christoph Wyen, Mounir Ait-khaled, Keith A. Pappa, Ruolan Wang, Peter A. Leone, Jonathan Wright, Brian Wynne, Jean van Wyk, Michael Aboud, Kimberly Y. Smith
Publicado 2022-01-01
Artículo -
12
Defect engineering of silicon with ion pulses from laser acceleration por Walid Redjem, Ariel J. Amsellem, Frances I. Allen, Gabriele Benndorf, Jianhui Bin, Stepan Bulanov, Eric Esarey, Leonard C. Feldman, Javier Ferrer Fernandez, Javier Garcia Lopez, Laura Geulig, Cameron R. Geddes, Hussein Hijazi, Qing Ji, Vsevolod Ivanov, Boubacar Kanté, Anthony Gonsalves, Jan Meijer, Kei Nakamura, Arun Persaud, Ian Pong, Lieselotte Obst-Huebl, Peter A. Seidl, Jacopo Simoni, Carl Schroeder, Sven Steinke, Liang Z. Tan, Ralf Wunderlich, Brian Wynne, Thomas Schenkel
Publicado 2023-03-01
Artículo